114809-62-0

Upstream product

• 114809-45-9 N-<3-(benzyloxy)propoxy>phthalimide 
• 4799-68-2 3-benzyloxypropan-1-ol 

Downstream Products

• 123240-67-5 6-<<3-(benzyloxy)propoxy>amino>-4-chloro-5-formamidopyrimidine 
• 116477-31-7 N-[4-(3-Benzyloxy-propoxyamino)-6-chloro-5-formylamino-pyrimidin-2-yl]-formamide 
• 116477-32-8 9(3-Benzyloxyprop-1-oxy)-6-chloro-2-formamidopurine 
• 114778-89-1 9-(3-benzyloxypropoxy)guanine 
• 114778-20-0 C₁₄H₁₈N₄O₃ 
• 114778-21-1 5-Amino-1-(3-benzyloxy-propoxy)-1H-imidazole-4-carboxylic acid amide 
• 118222-04-1 1-(3-Benzyloxypropoxy)-4-(1,2,4-triazol-1-yl)pyrimidin-2(1H)-one 
• 118222-01-8 1-(3-Benzyloxypropoxy)thymine 
• 118221-99-1 1-(3-Benzyloxypropoxy)uracil 
• 119080-68-1 1-(3-Benzyloxypropoxy)cytosine 
• 867168-92-1 2-amino-3-hydroxy-propionaldehyde O-(3-benzyloxy-propyl)-oxime 
• 116477-29-3 C₁₃H₂₀N₂O₂ 
• 118221-97-9 N-(3-Benzyloxypropoxy)urea 

Relevant academic research and scientific papers

Method for synthesizing azanol

The invention relates to a hydroxylamine synthesis method. The hydroxylamine synthesis method comprises the following steps: (A) enabling alcohol to react with alkyl sulfonyl halide in the presence of an acid-binding agent to obtain sulphonate; (B) enabling the obtained sulphonate in the step (A) to react with N-hydroxycyclodiimide in the presence of alkali to generate alkylate of the N-hydroxycyclodiimide; and (C) enabling the alkylate obtained in the step (B) to react with an aminolysis reagent or a hydrazinolysis reagent to obtain the hydroxylamine. The method is high in yield and suitable for large-scale industrial hydroxylamine synthesis.

A solid-phase approach to DDB derivatives

Since the discovery of 2,2′-dimethoxycarbonyl-4,4-dimethoxy-5,6, 5′,6′-biomethylenedioxy-biphenyl (DDB) as a potent anti-HBV agent, we have studied the structure-activity relationships of 4,4′-dimethoxy-5, 6,5′,6′-dimethenedioxy-2-alkyloxycarbonyl-2′-(4-substituted benzyl piperazin-1-yl)carbonyl-biphenyl as anti-HBV agents. Therefore, it is rational to extend this study to the 3,3′-disustituted-4,4′- dimethoxy-5,6,5′,6′-dimethenedioxy-2-alkyloxycarbonyl-2′- Serine derivatives. Thus, in an attempt to develop an efficient method for the preparation of a large number of DDB derivatives, the reaction between a DDB acid chloride and serine derivatives on solid support was studied. The structure of resulted compounds was confirmed by LC-MS and 1H NMR analysis. Compounds 2a, 2d, 2f, 2j showed in vitro anti-HBV activity without significant toxicity up to 100 μM.

N3 alkylated benzimidazole derivatives as MEK inhibitors

Disclosed are compounds of the formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein W, R1, R2, R7, R8, R9 and R10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.

SYNTHESIS OF 9-(3-HYDROXYPROPOXY)GUANINE, A NOVEL ANTIVIRAL ACYCLONUCLEOSIDE

Synthetic approaches to 9-(3-hydroxypropoxy)guanine (2) involving the intermediacy of either a 1-alkoxyimidazole (7) or a 4-alkoxyaminopyrimidine (13) are described.This 9-alkoxyguanine (2) has potent and selective anti-herpesvirus activity and is the first reported member of a new series of antiviral acyclonucleosides.